Dietary Polyphenols and Lipid Oxidation

This study has been completed.
Sponsor:
Collaborator:
Alpro Foundation
Information provided by (Responsible Party):
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01302639
First received: February 22, 2011
Last updated: September 8, 2014
Last verified: September 2014

February 22, 2011
September 8, 2014
February 2011
October 2013   (final data collection date for primary outcome measure)
postprandial fat oxidation [ Time Frame: 3 days ] [ Designated as safety issue: No ]

3 day supplementation of different combinations of polyphenols in a randomised crossover design in healthy overweight volunteers.

At the end of each supplementation period, postprandial fat oxidation is measured

Same as current
Complete list of historical versions of study NCT01302639 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Dietary Polyphenols and Lipid Oxidation
Dietary Polyphenols as Modulators of Lipid Oxidation and Mitochondrial Function in Overweight Volunteers

There are strong indications that (combinations of) polyphenols may be attractive candidates in the prevention of the metabolic syndrome and diabetes through modulation of pathways of fatty acid metabolism and mitochondrial function. We hypothesize that the combination of specific polyphenols, with partly distinct mechanisms of action, may have physiologically significant effects on fat oxidation through additive or synergistic effects, thereby improving body composition, insulin sensitivity and preventing type 2 diabetes. The following objective will be addressed in the current study:

(1) to test short term (3 day) effects of combinations of polyphenols (supplements of EGCG either in combination with resveratrol or with resveratrol and genistein) to affect systemic lipolysis and fat oxidation during overnight fasted conditions and after ingestion of a high fat meal in overweight subjects

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Obesity, Insulin Sensitivity, Type 2 Diabetes Mellitus
Dietary Supplement: Comparison of different combinations of polyphenols with respect to effects on fat oxidation
EGCG, resveratol and genistein
  • Experimental: EGCG and resveratrol
    Intervention: Dietary Supplement: Comparison of different combinations of polyphenols with respect to effects on fat oxidation
  • Experimental: EGCG, resveratrol and genistein
    Intervention: Dietary Supplement: Comparison of different combinations of polyphenols with respect to effects on fat oxidation
  • Placebo Comparator: placebo
    Intervention: Dietary Supplement: Comparison of different combinations of polyphenols with respect to effects on fat oxidation
Most J, Goossens GH, Jocken JW, Blaak EE. Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects. Int J Obes (Lond). 2014 May;38(5):698-706. doi: 10.1038/ijo.2013.231. Epub 2013 Dec 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
November 2013
October 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • overweight men and women (BMI≥25kg/m2- 29.9 kg/m2), aged 30-70 years, Caucasian, normal fasting glucose (< 6.1 mmol/L) and blood pressure (systolic blood pressure 100-140 mmHg, diastolic blood pressure 60-90 mmHg), weight stable in last 3 months (± 2kg). Exclusion criteria:

Exclusion Criteria:

  • women lactating, pregnant or (post)menopausal, regular smokers, people with intensive fitness training, eg. athletes (≥ 3 per week ≥ 1 hour training), habitual consumption of green tea (more than 1 cup per day) or products containing green tea extract, total caffeine consumption > 300 mg/day, alcohol intake >20 g/day, any dietary vitamins or dietary supplements, diabetes mellitus (defined as FPG ≥ 7.0 mmol/l and/or 2hPG ≥ 11.1 mmol/l); serious pulmonary, cardiovascular, hepatic or renal disease : history of cardiovascular disease, all other relevant medical disorders that potentially interfere with this trial, current use of medication interfering with study intervention or interfering with study endpoints/hypotheses.
Both
30 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01302639
MEC 10-03-032.7
No
Maastricht University Medical Center
Maastricht University Medical Center
Alpro Foundation
Not Provided
Maastricht University Medical Center
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP